KRAS and neoplasm: In an effort to understand real-world practices involving key clinical issues, physicians were questioned on: (a) Specific tests ordered for molecular diagnostics and (b) the impact of tumor sidedness on their first-line targeted therapy choice for patients with KRAS wildtype.